Equity · Healthcare
RYTM
NASDAQRhythm Pharmaceuticals (RYTM)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for RYTM to draw a line in its place.
- Market cap
- 7.4B USD
- Revenue, year to Dec 2025
- 189.8M USD
- EPS, diluted, year to Dec 2025
- −3.11 USD
- 52-week range
- 75.84 USD – 118 USD
- Avg volume
- 260.7K
as of Jul 17, 2026
Have Rhythm Pharmaceuticals (RYTM) insiders bought or sold shares recently?
RYTM has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 14 September 2026.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 14 Sep 2026 | Meeker David PPresident and CEO | Sell | 50,000 | 5.1M USD |
| 31 Aug 2026 | Smith Hunter CChief Financial Officer | Sell | 62,774 | 6.6M USD |
| 13 Aug 2026 | Lee Jennifer KaydenEVP, Head of North America | Sell | 75,834 | 8.9M USD |
| 13 Aug 2026 | Garfield AlastairChief Scientific Officer | Sell | 7,763 | 913K USD |
| 13 Aug 2026 | Shulman JosephChief Technical Officer | Sell | 5,079 | 608K USD |
| 12 Aug 2026 | Mazabraud YannEVP, Head of International | Sell | 57,000 | 6.6M USD |
| 22 Jun 2026 | TETRAULT LYNN A.Director | Sell | 37,000 | 3.7M USD |
| 15 May 2026 | German Christopher PaulCorporate Controller & CAO | Sell | 4,643 | 428K USD |
| 04 Mar 2026 | German Christopher PaulCorporate Controller & CAO | Sell | 5,614 | 503K USD |
| 19 Feb 2026 | Smith Hunter CChief Financial Officer | Sell | 4,385 | 444K USD |
| 17 Feb 2026 | Smith Hunter CChief Financial Officer | Sell | 3,569 | 362K USD |
| 12 Feb 2026 | Smith Hunter CChief Financial Officer | Sell | 1,592 | 156K USD |
| Sold | 23 open-market sales | 383,926 | $41.71M |
Showing the 12 most recent of 23 open-market trades in this window. The figures above count all of them.
45 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 14 Sep 2026 | Meeker David PPresident and CEO | Option exercise | 50,000 | 303K USD |
| 31 Aug 2026 | Smith Hunter CChief Financial Officer | Option exercise | 57,187 | 1.5M USD |
| 13 Aug 2026 | Lee Jennifer KaydenEVP, Head of North America | Option exercise | 56,601 | 997K USD |
| 13 Aug 2026 | Shulman JosephChief Technical Officer | Option exercise | 2,024 | 14K USD |
| 12 Aug 2026 | Mazabraud YannEVP, Head of International | Option exercise | 46,625 | 317K USD |
| 01 Jul 2026 | Garfield AlastairChief Scientific Officer | Option exercise | 4,445 | |
| 01 Jul 2026 | Garfield AlastairChief Scientific Officer | Tax withheld | 2,150 | 237K USD |
| 23 Jun 2026 | JEAN CHRISTOPHEDirector | Option exercise | 4,712 | |
| 23 Jun 2026 | MCGIRR DAVID W JDirector | Option exercise | 4,712 | |
| 23 Jun 2026 | TETRAULT LYNN A.Director | Option exercise | 4,712 | |
| 23 Jun 2026 | Arbuckle Stuart ADirector | Option exercise | 4,712 | |
| 23 Jun 2026 | GOOD JENNIFER LDirector | Option exercise | 4,712 |
Showing the 12 most recent of 45 compensation filings in this window. The figures above count all of them.
Which funds hold Rhythm Pharmaceuticals (RYTM)?
1 of the 45 institutional funds we track reported a Rhythm Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 10.1M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | New position | 105,999 | 10.1M USD |
What has been filed or recorded for Rhythm Pharmaceuticals (RYTM)?
The filings we hold for Rhythm Pharmaceuticals, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.61 USD | |
| 30 Sep 2026 | Financials | Total assets | 443.1M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 88.0M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.73 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.83 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −3.11 USD | |
| 31 Dec 2025 | Financials | Revenue | 189.8M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −196.5M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −3.11 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.82 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.75 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.81 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −4.34 USD |
Rhythm Pharmaceuticals (RYTM): frequently asked questions
What is Rhythm Pharmaceuticals’ market cap?
Rhythm Pharmaceuticals is worth 7.4B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.
What is Rhythm Pharmaceuticals’ revenue?
Rhythm Pharmaceuticals reported revenue of 189.8M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Rhythm Pharmaceuticals insiders bought or sold shares recently?
No Rhythm Pharmaceuticals insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 14 Sep 2026 (SEC Form 4). See Insiders
Which funds own Rhythm Pharmaceuticals?
1 of the 45 funds we track reported a Rhythm Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
When did Rhythm Pharmaceuticals last report earnings?
Rhythm Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.61 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings